加载中
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
前收盘价
US$80.35
−US$1.76 · -2.14%
盘后
US$80.35
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
日内区间
当前US$80.35
52周区间
当前US$80.35
盘中时间采用ET。市场数据可能有所延迟。
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
日内区间
当前US$80.35
52周区间
当前US$80.35
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 8.3万 USD | 2.7万 USD | 11.1万 USD | 11.4万 USD | 9.1万 USD |
| 毛利 | −8.3万 USD | −2.7万 USD | −11.1万 USD | −11.4万 USD | −9.1万 USD |
| 研究与开发 | 1.01亿 USD | 7506万 USD | 101.3万 USD | 446.4万 USD | 1383.2万 USD |
| 销售、一般及管理费用 | 2132.8万 USD | 1303.6万 USD | 617.2万 USD | 526.3万 USD | 541.2万 USD |
| 营业费用 | 1.22亿 USD | 8809.6万 USD | 718.5万 USD | 972.7万 USD | 1924.4万 USD |
| 利息收入 | 1663万 USD | 586.3万 USD | 195.7万 USD | 67.5万 USD | — |
| 利息支出 | — | 146.8万 USD | — | — | — |
| 折旧和摊销 | 8.3万 USD | 2.7万 USD | 11.1万 USD | 11.4万 USD | 9.1万 USD |
| 营业利润 | −1.22亿 USD | −8812.3万 USD | −729.6万 USD | −984.1万 USD | −1933.5万 USD |
| 净利润 | −1.05亿 USD | −8372.4万 USD | −533.9万 USD | −992.6万 USD | −1932.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$144.56
上涨空间 79.91%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2024年8月29日 | US$1.613Special | 2024年8月26日 | — |
除息 2024年8月29日
US$1.613
Special
2024年8月26日登记
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.6亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1.31亿1.32%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1.08亿0.14%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF5452.9万0.06%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO3820.81万0.27%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB3750.03万0.35%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO2681.49万0.15%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA2420.71万0.11%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
